Managing obesity and glycemic control in insulin-using patients: clinical relevance and practice recommendations

Challenges associated with insulin therapy in type 2 diabetes mellitus

Despite advances in treatment for type 2 diabetes in recent decades, many patients are failing to achieve adequate glycemic control. Poor glycemic control has been shown to have a detrimental effect on patients' health and well-being, and to have significant negative financial implications for both patients and healthcare systems. Insulin therapy has been proven to significantly reduce glycated hemoglobin levels; however, both patients and physicians can be reluctant to initiate insulin therapy. Research shows that both patient and provider factors contribute to a delay in initiation of insulin therapy. This review discusses the most common barriers contributing to this delay with potential solutions to overcome them.

The role of insulin detemir in overweight type 2 diabetes management

The recent evidence-based shift towards an algorithm of early initiation and aggressive titration of insulin therapy in the management of type 2 diabetes requires the use of an effective insulin formulation that is both safe and acceptable to patients and physicians alike. The advent of the long-acting insulin analogues, insulin detemir and glargine, in the last decade has revolutionized insulin therapy in type 2 diabetes. Their unique pharmacokinetic and pharmacodynamic properties have offered tangible advantage over the conventional intermediate and long-acting insulin preparations in terms of improving glucose control as well as reducing risk of hypoglycemia and weight gain. This review focuses on the pharmacodynamic properties of the long-acting insulin analogue detemir, the outcome of studies on its relative efficacy and safety as well as its proposed place in the management of type 2 diabetes.

Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes

PROBLEM

Obesity and type 2 diabetes have reached epidemic proportions in the United States. Obese patients are at especially high risk for the development of metabolic syndrome, a clustering of metabolic abnormalities associated with insulin resistance that usually precede the development of cardiovascular disease. Overweight or obesity, along with insulin resistance, is frequently present in people with type 2 diabetes.

METHODS

A literature search of the PubMed and MEDLINE databases, using the terms diabetes, obesity, metabolic syndrome, glycemic control, antidiabetic therapy, and insulin, was performed. Articles published between 1985 and 2006 that examined diabetes management in the obese population were selected and reviewed.

RESULTS

There is new evidence suggesting that tight glycemic control and earlier initiation of insulin therapy can improve outcomes in obese patients with type 2 diabetes, thereby reducing the risk for the development of both macrovascular and microvascular complications of the disease. Insulin also appears to exhibit anti-inflammatory effects, which may provide additional protection against the development of atherosclerosis. Despite the benefits of insulin therapy, many patients and physicians remain reluctant to start insulin due to concerns about weight gain.

CONCLUSION

Newer insulin formulations can effectively improve glycemic control without significant effects on patient weight and, therefore, may be particularly useful in patients who are overweight or obese. Implementation of comprehensive treatment regimens that emphasize dietary modification, physical activity, and exercise, and aggressive use of pharmacological agents to achieve tight glycemic control through physiological regimens offer the most promise for reducing long-term complications in obese patients with type 2 diabetes.

Controlling the ABCs of diabetes in clinical practice: a community-based endocrinology practice experience

AIMS

Determine A1C, blood pressure (BP), and total cholesterol (TC) (Diabetes ABCs) control in a community-based endocrinology practice (CBEP) and compare levels to national averages. Additionally, determine patient factors associated with ABC control.

METHODS

A retrospective chart audit of 395 consecutive patients seen for diabetes management was conducted for years 2000-2004 to examine levels of control of the ABCs. Multivariate models were used to determine patient factors associated with control.

RESULTS

Significantly more patients met the goal of A1C <7% in the CBEP compared to national estimates (CBEP: 47.1% vs. NHANES 1999-2000: 37%, p=0.003). Similar patterns were observed for BP (CBEP: 53.2% vs. NHANES 1999-2000: 35.8%, p<0.0001), TC (CBEP: 82% vs. NHANES 1999-2000: 48.2%, p<0.0001), and all three ABCs (CBEP: 22%, vs. NHANES 1999-2000: 7.3%, p<0.0001). The proportion of patients meeting all three ABC goals in the CBEP increased significantly over time (p<0.0001). Multivariate models demonstrated that patients not needing insulin (p<0.0001), and taking fewer BP (p<0.0001), and cholesterol-lowering medications (p<0.02) were significantly more likely to have ABCs in control.

CONCLUSIONS

Attainment of ABC goals is feasible in a CBEP and can be achieved at rates higher than national averages. Attention to factors that affect these goals is warranted.

Intensive diabetes therapy and body weight: focus on insulin detemir

Weight gain can be a significant barrier to the treatment of diabetes. Insulin detemir is a basal insulin analog that can help patients move safely toward glycemic targets with less weight gain. This review discusses the potential adverse effects of, and hypothesis for, weight gain resulting from intensive insulin management of diabetes. In addition, an assessment of all weight change data from clinical trials and observational studies involving insulin detemir are presented. Finally, we discuss how the ability of insulin detemir to closely mimic endogenous insulin secretion leads to more predictable glycemic control with reduced weight gain and provides patients with a more acceptable method of achieving glycemic control.

Challenges and strategies: weight management in type 2 diabetes

This article examines the link between obesity and type 2 diabetes and discusses some of the challenges health-care professionals face in helping people with diabetes achieve and maintain a healthy weight. Increasing numbers of people in both developed and developing countries are being classified as overweight or obese, which is resulting in growing numbers of people being diagnosed with type 2 diabetes. Worryingly this includes large numbers of children developing type 2 diabetes as the younger age groups are becoming overweight or obese. The health-care practitioner's role is explored and strategies to promote and achieve a healthy lifestyle for people with type 2 diabetes are offered. Such strategies are linked to obesity management through, diet, exercise and behavioural therapy.

Walnuts and dietary approaches to the prevention and management of abnormal lipid profiles in Type 2 diabetes mellitus

Type 2 diabetes mellitus is associated with an increased risk of coronary heart disease, reflected in the presence of abnormal lipid profiles. Increasing the intake of polyunsaturated fat at the same time as reducing saturated fat can alleviate these risk factors. Including walnuts in a ‘whole of diet’ approach to managing fat consumption can help to ensure that the desired fatty acid profile is achieved. This comes via a food matrix that also delivers anti-oxidants, fibre and protein that may provide additional nutritional benefits. Thus there is good reason to include walnuts in dietary advice for patients with Type 2 diabetes mellitus.

A graphical user interface for diabetes management that integrates glucose prediction and decision support

BACKGROUND

The promise of the Diabetes Control and Complications Trial (DCCT) has yet to be realized in clinical practice. Notwithstanding intensive education and intensified therapy, there is a distinct lack of a suitable alternative to the intensive decision support that was also provided in the DCCT. Recently, a novel glucose predicting engine has been developed and validated. Use of its predictions in decision support in respect to medication dosing, diet, exercise, and stress promises to empower patients to achieve better diabetes control while reducing hypoglycemia and preventing body weight gain. A graphical user interface (GUI) suitable for these purposes is here described.

METHODS

The kernel of the GUI is a registry database located on a server accessible to both patients and their providers. The patient-GUI includes the resources of the glucose predicting engine and user-friendly, intuitive means to enter body weight and all home-monitored blood glucose levels. In response, means to modify medication dosages (dosing decision support) and modify planned diet and physical activity (lifestyle decision support) are afforded the user. Each action is animated so that the patient can visually see the impact of his or her changes on predicted glucose outcomes and the pending risks of hypoglycemia.

RESULTS

A staged sequence of screens supports the self-management tasks, including selection of the current meal period, the entry of data, and documentation. The GUI returns current medications and presents up-down buttons for adjusting dosages, for changing carbohydrates, for changing exercise, and for predicting the effects of stress. For each adjustment, the impact on medications or predicted glycemia outcomes is animated.

CONCLUSIONS

A new GUI that incorporates a novel glucose predicting engine is intended for all insulin-treated patients with diabetes. It may help patients and their providers to realize better glycemic control and thereby achieve the promise of the DCCT.